Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
Completed
- Conditions
- Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
- Interventions
- Drug: Risk of selected safety events
- Registration Number
- NCT01276275
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for the first time.
A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 7200
Inclusion Criteria
- First time users of ticagrelor, clopidogrel and prasugrel, respectively
Exclusion Criteria
- Individuals with more than one of above three antiplatelet drugs dispensed the same day
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Exposure Group 3 Risk of selected safety events First time users of prasugrel Exposure Group 1 Risk of selected safety events First time users of ticagrelor Exposure Group 2 Risk of selected safety events First time users of clopidogrel
- Primary Outcome Measures
Name Time Method Drug utilization: Description of patient characteristics and drug usage Up to one year after entry into study cohort
- Secondary Outcome Measures
Name Time Method Follow-up of safety outcomes: First occurrence of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout Up to one year after entry into study cohort.
Trial Locations
- Locations (1)
Research Site
🇸🇪Stockholm, Sweden